Carboplatin

About

Therapy type: Chemotherapy

Therapy strategy: Platinum-based chemotherapy

Mappings

NCI Thesaurus: Carboplatin (coding:ncit:C1282)

RxNorm: carboplatin (coding:rxcui:40048, coding:omop:1344905)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
FDA (2) HC (1) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
FDA (2) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
FDA (2) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
FDA (4) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (4) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (4) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (2) HC (1) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel
FDA (4) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (4) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (2) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (2) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (2) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
FDA (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (2) HC (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (2) HC (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (2) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (2) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (2) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab
HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab